BiotechTubeBiotechTube
Home/Atea Pharmaceuticals/Marc Van Hulle
MV

Marc Van Hulle

Vice President, Finance

Atea Pharmaceuticals

Therapeutic Areas

Infectious DiseaseVirologyHepatology

Atea Pharmaceuticals Pipeline

DrugIndicationPhase
Bemnifosbuvir / RuzasvirHepatitis C Virus (HCV)Phase 3
AT-527 (Bemnifosbuvir)COVID-19 (SARS-CoV-2)Phase (Partnered)
AT-587Hepatitis E Virus (HEV)Preclinical

Leadership Team at Atea Pharmaceuticals

JS
Jean-Pierre Sommadossi, PhD
Founder, Chairman & Chief Executive Officer
AC
Andrea Corcoran
Chief Financial Officer & Executive Vice President, Legal
JH
Janet Hammond, MD, PhD
Chief Development Officer
AH
Arantxa Horga, MD
Chief Medical Officer
JV
John Vavricka
Chief Commercial Officer
AM
Adel Moussa, PhD
Executive Vice President, Chemistry
SG
Steven Good
Executive Vice President, Preclinical Science
NA
Nancy Agrawal, PhD
Executive Vice President, Preclinical Development
KP
Keith Pietropaolo
Executive Vice President, Clinical Sciences and Project Management
JW
Jayanthi Wolf, PhD
Executive Vice President, Regulatory Affairs
View full Atea Pharmaceuticals profile